Market DisruptionU.S. marketing of FYB201 (ranibizumab biosimilar) was paused by Sandoz, affecting revenue.
Regulatory And Commercial RisksRisks include failure of biosimilar candidates in clinical trials, failure to secure regulatory approval, failure to achieve commercial success due to market size, penetration rate, and competition, and potential dilution risk.
RevenueTotal revenue was €5.3M, missing our projection of €14.0M.